Genetics of autoimmune diseases - Disorders of immune homeostasis

Nature Reviews Genetics

Volumn 7, Issue 12, 2006, Pages 917-928

  Gregersen, Peter K ^a   Behrens, Timothy W ^b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; GENETIC ASSOCIATION; GENETIC VARIABILITY; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM;

MAMMALIA;

EID: 33845341462     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg1944     Document Type: Review

References (128)

1. Silverstein, A. M. Paul Ehrlich, archives and the history of immunology. Nature Immunol. 6, 639 (2005).
2. Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
3. Hallert, E., Husberg, M., Jonsson, D. & Skogh, T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 43, 1374-1382 (2004).
4. Kobelt, G., Berg, J., Atherly, D. & Hadjimichael, O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 66, 1696-1702 (2006).
5. Ashwood, P., Wills, S. & Van de Water, J. The immune response in autism: a new frontier for autism research. J. Leukoc. Biol. 80, 1-15 (2006).
6. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003).
7. Hoppu, S., Ronkainen, M. S., Kulmala, P., Akerblom, H. K. & Knip, M. GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetes. Clin. Exp. Immunol. 136, 120-128 (2004).
8. Strieder, T. G., Prummel, M. F., Tijssen, J. G., Endert, E. & Wiersinga, W. M. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin. Endocrinol. 59, 396-401 (2003).
9. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
10. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606. (2001).
11. Shiina, T., Inoko, H. & Kulski, J. K. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64, 631-649 (2004).
12. Criswell, L. A. et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76, 561-571 (2005).
13. Michel, M. et al. Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families. Medicine 80, 153-158 (2001).
14. Kyewski, B. & Klein, L. A central role for central tolerance. Annu. Rev. Immunol. 24, 571-606 (2006).
15. Liston, A., Lesage, S., Gray, D. H., Boyd, R. L. & Goodnow, C. C. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol. Rev. 204, 87-101 (2005).
16. + regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. 305, 51-66 (2006). References 14-16 provide a comprehensive discussion of the various mechanisms of T-cell tolerance. Sakaguchi, a pioneer in defining regulatory T cells, provides an up-to-date discussion of this fast-moving field.
17. Sakaguchi, S. & Sakaguchi, N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int. Rev. Immunol. 24, 211-226 (2005).
18. Apostolou, I. & von Boehmer, H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199, 1401-1408 (2004).
19. + regulatory T cells by TGFβ induction of transcription factor FOXP3. J. Exp. Med. 198, 1875-1886 (2003).
20. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T-cell development by the transcription factor FOXP3. Science 299, 1057-1061 (2003).
21. + regulatory T cells. Nature. Immunol. 4, 330-336 (2003).
22. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in FOXP3-expressing regulatory T cells. Nature. Immunol. 6, 1142-1151 (2005).
23. + regulatory T cells control autoimmunity? Curr. Opin. Immunol. 17, 638-642 (2005).
24. Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 298, 1395-1401 (2002). This seminal paper demonstrates the importance of AIRE in regulating the thymic expression of self antigens and its role in autoimmunity.
25. Anderson, M. S. et al. The cellular mechanism of AIRE control of T-cell tolerance. Immunity 23, 227-239 (2005).
26. Nagamine, K. et al. Positional cloning of the APECED gene. Nature Genet. 17, 393-398 (1997).
27. Eisenbarth, G. S. & Gottlieb, P. A. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350, 2068-2079 (2004).
28. Takase, H. et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int. Immunol. 17, 1131-1140 (2005).
29. Barratt, B. J. et al. Remapping the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes 53, 1884-1889 (2004).
30. Pugliese, A. et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nature Genet. 15, 293-297 (1997).
31. Vafiadis, P. et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nature Genet. 15, 289-292 (1997).
32. Chentoufi, A. A. & Polychronakos, C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 51, 1383-1390 (2002).
33. Kent, S. C. et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435, 224-228 (2005).
34. Giraud, M. et al. Transcriptional control of CHRNA1 gene in thymus by a promoter SNP associated with onset of autoimmune myasthenia gravis. Clinical Immunol. 119, 512 (2006).
35. Dechairo, B. M. et al. Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur. J. Hum. Genet. 13, 1223-1230 (2005).
36. Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the ZAP70 gene causes autoimmune arthritis in mice. Nature 426, 454-460 (2003).
37. Wildin, R. S., Smyk-Pearson, S. & Filipovich, A. H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39, 537-545 (2002).
38. Wildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature Genet. 27, 18-20 (2001).
39. Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genet. 27, 68-73 (2001).
40. + T regulatory cells. Nature Immunol. 4, 337-342 (2003).
41. Sakaguchi, S., Fukuma, K., Kuribayashi, K. & Masuda, T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161, 72-87 (1985).
42. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
43. +) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
44. Fehervari, Z., Yamaguchi, T. & Sakaguchi, S. The dichotomous role of IL-2: tolerance versus immunity. Trends Immunol. 27, 109-111 (2006).
45. Vella, A. et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag singlenucleotide polymorphisms. Am. J. Hum. Genet. 76, 773-779 (2005).
46. Keir, M. E. & Sharpe, A. H. The B7/CD28 costimulatory family in autoimmunity. Immunol. Rev. 204, 128-143 (2005).
47. van Berkel, M. E. & Oosterwegel, M. A. CD28 and ICOS: similar or separate costimulators of T cells? Immunol. Lett. 105, 115-122 (2006).
48. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature Rev. Immunol. 4, 336-347 (2004).
49. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
50. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995).
51. Gough, S. C., Walker, L. S. & Sansom, D. M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev. 204, 102-115 (2005).
52. Yanagawa, T., Hidaka, Y., Guimaraes, V., Soliman, M. & DeGroot, L. J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab. 80, 41-45 (1995).
53. Nistico, L. et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet. 5, 1075-1080 (1996).
54. Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511 (2003). The first detailed, although still incomplete, analysis of the molecular basis of CTLA associations with autoimmune disease. See reference 51 for a more recent review.
55. Plenge, R. M. et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 77, 1044-1060 (2005).
56. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
57. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
58. Prokunina, L. et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genet. 32, 666-669 (2002).
59. Martin-Orozco, N. & Dong, C. New battlefields for costimulation. J. Exp. Med. 203, 817-820 (2006).
60. Holets, L. M., Hunt, J. S. & Petroff, M. G. Trophoblast CD274 (B7-H1) is differentially expressed across gestation: influence of oxygen concentration. Biol. Reprod. 74, 352-358 (2006).
61. Keir, M. E. et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883-895 (2006).
62. Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
63. Bottini, N., Vang, T., Cucca, F. & Mustelin, T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18, 207-213 (2006).
64. Wu, J. et al. Identification of substrates of human protein tyrosine phosphatase PTPN22. J. Biol. Chem. 281, 11002-11010 (2006).
65. Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genet. 36, 337-338 (2004).
66. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330-337 (2004).
67. Smyth, D. et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53, 3020-3023 (2004).
68. Kyogoku, C. et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75, 504-507 (2004).
69. Vandiedonck, C. et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59, 404-407 (2006).
70. Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genet. 37, 1317-1319 (2005).
71. Hasegawa, K. et al. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303, 685-689 (2004). These two papers present contrasting evidence for the mechanisms by which PTPN22 alleles predispose to autoimmunity. Vang et al. provide evidence for the gain of function of PTPN22 risk alleles, whereas studies in knockout mice (Hasegawa et al.) indicate that PTPN22 has predominantly negative regulatory effects in T cells.
72. Gregersen, P. K., Lee, H. S., Batliwalla, F. & Begovich, A. B. PTPN22: setting thresholds for autoimmunity. Semin. Immunol. 18, 214-223 (2006).
73. Siminovitch, K. A. PTPN22 and autoimmune disease. Nature Genet. 36, 1248-1249 (2004).
74. Gregersen, P. K. Gaining insight into PTPN22 and autoimmunity. Nature Genet. 37, 1300-1302 (2005).
75. Begovich, A. B. et al. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am. J. Hum. Genet. 76, 184-187 (2005).
76. van Oene, M. et al. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 52, 1993-1998 (2005).
77. Carlton, V. E. et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 77, 567-581 (2005).
78. Marchini, J., Cardon, L. R., Phillips, M. S. & Donnelly, P. The effects of human population structure on large genetic association studies. Nature Genet. 36, 512-517 (2004).
79. Seldin, M. et al. European population substructure: clustering of northern and southern populations. PLoS Genet. 2, 1339-1351 (2006).
80. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nature Genet. 38, 904-909 (2006).
81. Nimmerjahn, F. & Ravetch, J. V. Fcaγ receptors: old friends and new family members. Immunity 24, 19-28 (2006).
82. Takai, T. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25, 1-18 (2005).
83. Su, K. et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcaγRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J. Immunol. 172, 7192-7199 (2004).
84. Blank, M. C. et al. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 117, 220-227 (2005).
85. Chadha, S. et al. Haplotype structure of TNFRSF5-TNFSF5 (CD40-CD40L) and association analysis in systemic lupus erythematosus. Eur. J. Hum. Genet. 13, 669-676 (2005).
86. Sontheimer, R. D., Racila, E. & Racila, D. M. C1Q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J. Invest. Dermatol. 125, 14-23 (2005).
87. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
88. Meylan, E., Tschopp, J. & Karin, M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
89. Schreiber, S., Rosenstiel, P., Albrecht, M., Hampe, J. & Krawczak, M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nature Rev. Genet. 6, 376-388 (2005).
90. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002). This groundbreaking study demonstrates that TLRs can co-stimumlate B-cell activation in the absence of T-cell help.
91. Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G. & Marshak-Rothstein, A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27-42 (2005).
92. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
93. Ronnblom, L., Eloranta, M. L. & Alm, G. V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54, 408-420 (2006).
94. Baechler, E. C., Gregersen, P. K. & Behrens, T. W. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807 (2004).
95. Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005).
96. Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genet. 38, 550-555 (2006). These two studies provide definitive evidence for the involvement of IRF5 in genetic susceptibility to SLE, therefore linking TLR signalling with abnormalities of interferon regulation in this disease (also see reference 93 for a review).
97. Morley, M. et al. Genetic analysis of genome-wide variation in human gene expression. Nature 430, 743-747 (2004).
98. Thurman, J. M. & Holers, V. M. The central role of the alternative complement pathway in human disease. J. Immunol. 176, 1305-1310 (2006).
99. Pickering, M. C., Botto, M., Taylor, P. R., Lachmann, P. J. & Walport, M. J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76, 227-324 (2000).
100. Russell, A. I. et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet. 13, 137-147 (2004).
101. Werth, V. P., Berlin, J. A., Callen, J. P., Mick, R. & Sullivan, K. E. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J. Invest. Dermatol. 119, 1394-1399 (2002).
102. Kravitz, M. S., Pitashny, M. & Shoenfeld, Y. Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J. Clin. Immunol. 25, 582-591 (2005).
103. Subramanian, S. et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103, 9970-9975 (2006).
104. Pisitkun, P. et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672 (2006). These two recent studies provide direct evidence for the involvement of TLRs (Tlr7) in mouse models of autoimmunity, setting the stage for a further investigation of the role of TLR7 in humans, and further supporting the involvement of innate immune mechanisms in the development of autoimmunity.
105. Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nature Genet. 34, 395-402 (2003).
106. Alarcon, G. S. et al. Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement. Lupus 15, 26-31 (2006).
107. Krishnan, E. & Hubert, H. B. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann. Rheum. Dis. 65, 1500-1505 (2006).
108. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A. & Contopoulos-Ioannidis, D. G. Replication validity of genetic association studies. Nature Genet. 29, 306-309 (2001).
109. International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299-320 (2005).
110. Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005).
111. Pritchard, J. K. & Cox, N. J. The allelic architecture of human disease genes: common disease-common variant. or not? Hum. Mol. Genet. 11, 2417-2423 (2002).
112. Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases and complex traits. Nature Rev. Genet. 6, 95-108 (2005).
113. Wang, W. Y., Barratt, B. J., Clayton, D. G. & Todd, J. A. Genome-wide association studies: theoretical and practical concerns. Nature Rev. Genet. 6, 109-118 (2005).
114. Costenbader, K. H., Feskanich, D., Mandl, L. A. & Karlson, E. W. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am. J. Med. 119, 503.e1-503.e9 (2006).
115. Klareskog, L. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54, 38-46 (2006). This report provides a compelling recent example of a gene-environment interaction in the development of autoimmunity.
116. Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155-163 (2000).
117. Irigoyen, P. et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum. 52, 3813-3818 (2005).
118. Berglin, E. et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 6, R303-R308 (2004).
119. Kuhn, K. A. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961-973 (2006).
120. James, J. A. et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44, 1122-1126 (2001).
121. Manolio, T. A., Bailey-Wilson, J. E. & Collins, F. S. Genes, environment, and the value of prospective cohort studies. Nature Rev. Genet. 7, 812-820 (2006).
122. Vyse, T. J. & Todd, J. A. Genetic analysis of autoimmune disease. Cell 85, 311-318 (1996).
123. Redondo, M. J. & Eisenbarth, G. S. Genetic control of autoimmunity in type I diabetes and associated disorders. Diabetologia 45, 605-622 (2002).
124. Ban, Y. & Tomer, Y. Susceptibility genes in thyroid autoimmunity. Clin. Dev. Immunol. 12, 47-58 (2005).
125. Barcellos, L. F. et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72, 710-716 (2003).
126. Graham, R. R. et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am. J. Hum. Genet. 71, 543-553 (2002).
127. Hall, F. C. et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. QJM 89, 821-829 (1996).
128. Prokunina, L. et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 50, 1770-1773 (2004).